Identification of NPTX2 as a prognostic biomarker of Alzheimer’s disease through a longitudinal CSF proteomics study in ADNI subjects
Libiger O, Shaw L, Watson M, Nairn A, Umaña K, Canet‐Avilés R, Jack C, Breton Y, Cortes L, Chelsky D, Spellman D, Baker S, Raghavan N, Potter W. Identification of NPTX2 as a prognostic biomarker of Alzheimer’s disease through a longitudinal CSF proteomics study in ADNI subjects. Alzheimer's & Dementia 2020, 16 DOI: 10.1002/alz.047605.Peer-Reviewed Original ResearchP-Tau 181Alzheimer's diseasePrognostic biomarkerRate of declineADNI subjectsLongitudinal changesTau-tangle pathologyBaseline clinical diagnosisAssociation of changesPre-specified analysis planMild cognitive impairmentTangle pathologyClinical progressionMixed-effects linear modelNegative subjectsClinical prognosisDisease continuumAdditional biomarkersAmyloid plaquesDrug development effortsNormal subjectsSubset of individualsRetrospective investigationBiomarker profilesPathologic processes